You are here

Long-Acting Regimen of Cabotegravir and Rilpivirine Shows Sustained Virological Response and Good Tolerability in Patients with HIV

Injectable Combination Reduces Number of Annual Doses from 365 to 12

The injectable two-drug regimen of cabotegravir and rilpivirine (ViiV Healthcare, Brentford, England) could provide an alternative to daily tablets for patients with HIV, reducing the number of annual doses from 365 to 12.

Data from the LATTE-2 clinical trial showed durable treatment effects. At 160 weeks, 90% (n = 104/115) of patients who received the regimen every eight weeks and 83% (n = 95/115) of patients who received the regimen every four weeks remained virally suppressed. Patients in the oral comparator arm who switched to the injectable regimen at week 96 showed viral suppression rates of 97% (n = 33/34) and 100% (n = 10/10), respectively.

The most common adverse events included nasopharyngitis (38%), diarrhea (22%), and headache (22%). A majority of participants reported an injection-site reaction (ISR), 85% mild and 14% moderate, through week 160. Eighty-seven percent of ISRs resolved within seven days.

Sources: Seeking Alpha, October 29, 2018; ViiV Healthcare, October 30, 2018

Recent Headlines

First Devices Cleared for Diagnostic Testing Via Throat, Rectum Specimens
First New Medication for Seizure Clusters in More Than Two Decades
Novel, Low-cost Device Highly Accurate at Screening Newborn Jaundice
Mode Delivers Antivirals Safely, Cheaply to Remote Regions
Averts Disease Worsening, Reduces Potential for Blindness
Risk May Remain for 6 Months After Treatment
FDA Removes Boxed Warning With Drug’s Fifth Approval
Overeager Use of Recommendations Creates Problems
Artificial Intelligence Enables Platform to Detect Amyloid PET Status